#pneumonia — Saturday, October 03, 2026 (1 items)
| 1 | ℹ |
Ceftazidime-avibactam for the treatment of infections caused by carbapenem-resistant Gram-negative pathogens in Chinese patients: A phase IV, multi-center, open‑label study.
(linkinghub.elsevier.com)
|
International Journal of Antimicrobial Agents 2026-10-03 | #amr #carbapenem-resistance #pneumonia #clinical trial #gram-negative |